Abstract
Background/Aims: We aimed to clarify the association of hepatitis B surface antigen (HBsAg)/hepatitis B core antigen (HBcAg) with the disease status and treatment response in patients with chronic hepatitis B (CHB). Methods: We investigated 171 biopsy-proven entecavir-treated CHB patients (109 hepatitis B e antigen [HBeAg]-positive, 62 HBeAg-negative). HBcAg expression was positive when ≥10% of hepatocytes stained, and classified into nuclear, mixed, and cytoplasmic patterns. HBsAg expressions were intracytoplasmic (diffuse, globular, and submembranous) and membranous. The histologic activity index (HAI) and fibrosis stage followed Ishak system. Results: In HBeAg-positive patients, older age, increased HAI score, advanced fibrosis, and reduced viral load were observed when HBcAg expression shifted from nucleus to cytoplasm in HBcAg-positive patients, and HBsAg expression from non-submembranous to submembranous in HBcAg-negative patients (all, p<0.05). In HBeAg-negative patients, only intracytoplasmic HBsAg expression patterns had clinical relevance with decreased ALT levels and viremia. In HBeAg-positive patients without favorable predictors of virologic response, negative HBcAg and membranous HBsAg expression predicted greater virologic response (both, p<0.05). The probability of HBeAg seroclearance was higher in patients with increased HAI or lacking HBcAg expression (both, p<0.05). Higher serum HBsAg levels and hepatocyte HBcAg positivity were associated with reduced serum HBsAg during first and post-first year treatment, respectively (both, p<0.05). Conclusions: Hepatocyte HBcAg/HBsAg expression is a good marker for disease status and predicting treatment response.
| Original language | English |
|---|---|
| Pages (from-to) | 417-425 |
| Number of pages | 9 |
| Journal | Gut and Liver |
| Volume | 11 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2017 May 1 |
Fingerprint
Keywords
- Hepatitis B core antigens
- Hepatitis B surface antigens
- Hepatitis B, chronic
- Histologic activity index
ASJC Scopus subject areas
- Hepatology
- Gastroenterology
Cite this
Expression of hepatocyte hepatitis B core antigen and hepatitis B surface antigen as a marker in the management of chronic hepatitis B patients. / Yim, Sun Young; Kim, Tae Hyung; Jun, Suh Sang; Kim, Eun-Sun; Keum, Bora; Seo, Yeon Seok; Yim, Hyung Joon; Jeen, Yoon Tae; Chun, Hoon-Jai; Lee, Hong Sik; Um, Soon-Ho; Kim, Chang Duck; Won, Nam Hee; Ryu, Ho Sang.
In: Gut and Liver, Vol. 11, No. 3, 01.05.2017, p. 417-425.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Expression of hepatocyte hepatitis B core antigen and hepatitis B surface antigen as a marker in the management of chronic hepatitis B patients
AU - Yim, Sun Young
AU - Kim, Tae Hyung
AU - Jun, Suh Sang
AU - Kim, Eun-Sun
AU - Keum, Bora
AU - Seo, Yeon Seok
AU - Yim, Hyung Joon
AU - Jeen, Yoon Tae
AU - Chun, Hoon-Jai
AU - Lee, Hong Sik
AU - Um, Soon-Ho
AU - Kim, Chang Duck
AU - Won, Nam Hee
AU - Ryu, Ho Sang
PY - 2017/5/1
Y1 - 2017/5/1
N2 - Background/Aims: We aimed to clarify the association of hepatitis B surface antigen (HBsAg)/hepatitis B core antigen (HBcAg) with the disease status and treatment response in patients with chronic hepatitis B (CHB). Methods: We investigated 171 biopsy-proven entecavir-treated CHB patients (109 hepatitis B e antigen [HBeAg]-positive, 62 HBeAg-negative). HBcAg expression was positive when ≥10% of hepatocytes stained, and classified into nuclear, mixed, and cytoplasmic patterns. HBsAg expressions were intracytoplasmic (diffuse, globular, and submembranous) and membranous. The histologic activity index (HAI) and fibrosis stage followed Ishak system. Results: In HBeAg-positive patients, older age, increased HAI score, advanced fibrosis, and reduced viral load were observed when HBcAg expression shifted from nucleus to cytoplasm in HBcAg-positive patients, and HBsAg expression from non-submembranous to submembranous in HBcAg-negative patients (all, p<0.05). In HBeAg-negative patients, only intracytoplasmic HBsAg expression patterns had clinical relevance with decreased ALT levels and viremia. In HBeAg-positive patients without favorable predictors of virologic response, negative HBcAg and membranous HBsAg expression predicted greater virologic response (both, p<0.05). The probability of HBeAg seroclearance was higher in patients with increased HAI or lacking HBcAg expression (both, p<0.05). Higher serum HBsAg levels and hepatocyte HBcAg positivity were associated with reduced serum HBsAg during first and post-first year treatment, respectively (both, p<0.05). Conclusions: Hepatocyte HBcAg/HBsAg expression is a good marker for disease status and predicting treatment response.
AB - Background/Aims: We aimed to clarify the association of hepatitis B surface antigen (HBsAg)/hepatitis B core antigen (HBcAg) with the disease status and treatment response in patients with chronic hepatitis B (CHB). Methods: We investigated 171 biopsy-proven entecavir-treated CHB patients (109 hepatitis B e antigen [HBeAg]-positive, 62 HBeAg-negative). HBcAg expression was positive when ≥10% of hepatocytes stained, and classified into nuclear, mixed, and cytoplasmic patterns. HBsAg expressions were intracytoplasmic (diffuse, globular, and submembranous) and membranous. The histologic activity index (HAI) and fibrosis stage followed Ishak system. Results: In HBeAg-positive patients, older age, increased HAI score, advanced fibrosis, and reduced viral load were observed when HBcAg expression shifted from nucleus to cytoplasm in HBcAg-positive patients, and HBsAg expression from non-submembranous to submembranous in HBcAg-negative patients (all, p<0.05). In HBeAg-negative patients, only intracytoplasmic HBsAg expression patterns had clinical relevance with decreased ALT levels and viremia. In HBeAg-positive patients without favorable predictors of virologic response, negative HBcAg and membranous HBsAg expression predicted greater virologic response (both, p<0.05). The probability of HBeAg seroclearance was higher in patients with increased HAI or lacking HBcAg expression (both, p<0.05). Higher serum HBsAg levels and hepatocyte HBcAg positivity were associated with reduced serum HBsAg during first and post-first year treatment, respectively (both, p<0.05). Conclusions: Hepatocyte HBcAg/HBsAg expression is a good marker for disease status and predicting treatment response.
KW - Hepatitis B core antigens
KW - Hepatitis B surface antigens
KW - Hepatitis B, chronic
KW - Histologic activity index
UR - http://www.scopus.com/inward/record.url?scp=85018725095&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018725095&partnerID=8YFLogxK
U2 - 10.5009/gnl16148
DO - 10.5009/gnl16148
M3 - Article
VL - 11
SP - 417
EP - 425
JO - Gut and Liver
JF - Gut and Liver
SN - 1976-2283
IS - 3
ER -